Clinical Trial Management System Market Size & Share 2022 to 2030
Market Size by Component (Software, Services), by Product (Enterprise-based, Site-based), by Delivery Mode (Web, Cloud, On Premise), by End Use (Pharma & Biopharma Companies, CROs) & Forecast.
Report ID: GMI1155
|
Published Date: July 2022
|
Report Format: PDF
Download Free PDF
Authors:
Mariam Faizullabhoy, Gauri Wani
Clinical Trial Management System Market Size
Clinical Trial Management System Market size accounted for about USD 1.2 billion in 2021 and is estimated to grow with a 11.4% market CAGR between 2022 to 2030, owing to the rising focus of the healthcare sector in research and development activities worldwide.
Many large-scale pharmaceutical and biotech industry participants are noted to be engaged in constant research in order to develop novel products as well as to sustain in the market. For instance, according to the UNESCO Institute for Statistics (UIS), in 2021, the global R&D investment surpassed USD 1.7 trillion. Around ten countries accounted for nearly 80% of all R&D spending.
Several countries have committed to further enhance the public and corporate R&D spending, as well as the number of researchers, by 2030 as part of the Sustainable Development Goals (SDGs). Furthermore, one of the primary value drivers for research-based pharmaceutical businesses is innovative medications addressing the unmet medical needs. Owing to enormous growth in R&D activities, having essential tools to plan, manage and track clinical studies effectively is need of the hour. Hence, eClinical solutions, such as clinical trial management system (CTMS), are gaining market prominence.
The emergence of the COVID-19 pandemic significantly impacted the overall healthcare sector, disrupting the activities of virtually every organization operating within. To conduct clinical trials smoothly in healthcare and life science industry, where physical access to patients was not possible, using new ways for patient monitoring and caring had become necessary. Due to which the previously present data collection methods, CTMS which were not utilized before, were quickly adopted in clinical trials during COVID outbreak.
Although, these means were available before, the pandemic acted as a catalyst in their increased market usage. With the introduction of CTMS, new approaches and technology in clinical trials specifically the one’s related to remote data collection from patients increased the data variety and volume. As a result, majority positive impacts of clinical trial approaches newly implemented during the pandemic were due to the data. The respondents using CTMS and other new methods of data collection in clinical trials found their data to be well timed, accurate, frequent, and more robust. However, many clinical trials were suspended or postponed due to imposed lockdowns and other restrains due to government rules.
Increasing clinical trial activity is expected to spur the market statistics
The number of clinical trials has significantly increased in the past two decades. This is because of increasing penetration of cutting-edge medical technologies coupled with the rising demand for innovative medications with higher efficacy.
For instance, as of June 2022, according to the U.S. National Library of Medicine, 419,632 clinical studies were registered globally, with nearly 77% interventional studies and 22% observational studies. Also, according to the WHO International Clinical Trials Registry Platform (ICTRP), during the period 1999-2021, the U.S. (157,618) had the maximum clinical trials registered, followed by China (80,333), and Japan (57,754).
Clinical trial management system is both cost and time effective, as these are employed to collect and organise data and can be shared with several care providers and dispersed across multiple systems. These technologies can help with site identification and recruiting, as well as control and tracking of participant enrolment and the database of participants. Therefore, increasing clinical trial volume is contributing to the rising market demand for such CTMS solutions to effectively manage the clinical studies.
High cost of clinical trial management system may hamper the market demand
The high costs associated with clinical trial management system can potentially limit its market growth. Procurement, installation, and maintenance cumulatively surge the overall cost required for the adoption of CTMS solutions. On premise and SaaS-based systems both include installation fees. Additional setup, customization costs are charged to companies based on the distinctive organizational and study-specific demands. There are different cost structures observed with respect to number of users and number of sites under consideration. Certain contract or commitment term fees also need to be considered for CTMS along with periodic maintenance and upgradation of systems.
Clinical Trial Management System Market Analysis
Based on component, the market for clinical trial management system is classified into software and services. The software segment accounted for USD 897.3 million revenue in 2021 and is expected to dominate from 2022 to 2030 due to its high utilization and increased adoption in clinical trials. Various biotechnology, pharmaceutical companies and other life science organizations promoting research constantly conduct complex clinical trials. These trials are aimed at discovering novel medicines and medical devices.
With the increasing clinical trials activity and multi-site clinical trials gaining momentum, a need for effective tools to manage the studies with ease, maintain data with accuracy and manage the operational aspects of clinical studies also increases. Using software-based tools enables the sponsors to manage clinical trials efficiently.
The market for clinical trial management system is segmented by product into enterprise-based and site-based. The enterprise-based market segment is expected to witness a lucrative CAGR of 11.4% between 2022 and 2030. Enterprise based clinical trial management system is versatile and can be customized as per requirements. Such clinical trial management system feature functionalities related to documents, worksheets, calendars, schedules, contacts, payments, milestones etc. Enterprise based clinical trial management system solutions are also noted to be scalable to cater to the requirements of small, medium, and large-scale organizations. Therefore, the enterprise-based clinical trial management system market is expected to witness a significant demand throughout the forecast period.
Based on delivery mode, the clinical trial management system market value is segmented into web based, cloud based and on-premises. Web based segment dominated the global market accounting for over 59% market proportion in 2021 and is expected to witness lucrative growth over the forecast period. The web-based is highly effective, due to the ability of being adopted for diverse study designs and having multiple functionalities.
The clinical trial management system market share is segmented on the basis of end-use into pharmaceutical and biopharmaceutical companies and clinical research organization, among others. The pharmaceutical and biopharmaceutical companies are expected to register a healthy growth rate of 10.6% over the forecast period. The increasing demand for developing novel products for chronic illnesses as well as innovative medical devices compels the manufacturers/sponsors to significantly invest in research & development activities, including drug discovery and clinical trials.
Further, with an increasing number of novel diseases, such as coronavirus, spreading across geographies further propels the demand for developing targeted diagnostic devices as well as vaccines and related medications. Additionally, the increasing competition among large-scale pharma companies also emphasizes on novel product development to enhance the product portfolios.
North America clinical trial management system market is anticipated to surpass USD 1.5 billion by 2030. The rising clinical trial activity in North America coupled with higher cost of clinical operations in the region as compared to countries of Asia Pacific and Latin America are some of the prime factors for the regional dominance in the global CTMS market.
For instance, according to the WHO International Clinical Trials Registry Platform (ICTRP), between 1999 and 2021, the U.S. reported the highest number of clinical trials. It is evident that major pharma and biotech companies in the region heavily invest in research activities and are competing to discover and develop innovative medicines with greater efficacy. Also, well defined government regulations and support to the pharmaceutical industry is expected to encourage the clinical trials. These factors, coupled with a significantly high adoption rate for integrating digital solutions throughout clinical trials leads to an increasing employment of CTMS. CTMS also enables to organize & evaluate the clinical study data for regulatory submissions.
Clinical Trial Management System Market Share
Major players operating in the clinical trial management system industry include
These players opt for various inorganic growth strategies such as partnerships, collaborations, mergers and acquisitions and product launch to create a global footprint and industry competition.
Some of the recent industry developments:
The clinical trial management system market report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD from 2022 to 2030, for the following segments:
Click here to Buy Section of this Report
By Components
By Product
By Delivery Mode
By End-use
The above information is provided for the following regions and countries:
By Region
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →